50th week of 2021 patent applcation highlights part 24 |
Patent application number | Title | Published |
20210388313 | ORGANOID PRODUCED USING CARRIER FOR CELL CULTURE, AND METHOLD FOR EVALUATING DRUG TOXICITY USING SAME - The present invention relates to an organoid and, more specifically, to an organoid and a use thereof, the organoid being produced using a carrier for cell culture which comprises microcapsules containing gelatin, a natural polymer, an oil, and an oil thickener. When used as a carrier for cell culture in culturing cells, the microcapsules containing a natural oil, according to the present invention, have the effects of improving adhesion and survival of the cells and inducing maturation of the cultured cells. The organoid produced by culturing cells using the carrier for cell culture has been confirmed to have the function of the organ concerned and, when treated with a drug, react to the toxicity of the drug and thus may be variously employed in the development of new drugs, disease research, and the field of artificial organ development. | 2021-12-16 |
20210388314 | MICROCAPSULES CONTAINING NATURAL OIL AND PREPARATION METHOD THEREFOR - The present invention relates to microcapsules comprising natural oil and, more specifically, to microcapsules which contain gelatin, natural polymers, oil, and an oil thickener and have enhanced mechanical properties, and a preparation method therefor. The microcapsules comprising natural oil according to the present invention have remarkably enhanced mechanical properties and retention properties, and when co-cultured with cells, the microcapsules provide the effect of inducing maturation of the cells, and thus may be used in various fields of microcarriers, cell cultures, and co-culture systems. | 2021-12-16 |
20210388315 | ISOLATION AND CULTIVATION OF MUSCLE AND FAT CELLS FROM CRUSTACEANS - The present disclosure is directed to methods for the formation and production of renewable muscle and/or fat primary cell lines, immortalized cell lines, and stem cell lines from shrimp, prawn, crab, crayfish, and/or lobster species and the cell lines themselves as well as human and animal consumable meat products produced therefrom. | 2021-12-16 |
20210388316 | PREPARATION OF RETINAL PIGMENT EPITHELIUM CELLS - A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed. | 2021-12-16 |
20210388317 | HIGH-EFFICIENCY METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS - An object of the present invention is to improve the efficiency of a method for producing chimeric antigen receptor (CAR)-expressing cells. The present invention provides a method for producing genetically modified mammalian cells, comprising the steps of: a) introducing a polynucleotide encoding a chimeric antigen receptor (CAR) protein to a cell population comprising T cells derived from a mammal by a transposon method to obtain a genetically modified cell population; b) providing an endogenous cell population derived from the mammal expressing a protein that binds to the CAR; and c) coculturing the genetically modified cell population of the step a) and the endogenous cell population of the step b). | 2021-12-16 |
20210388318 | USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS - Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004). | 2021-12-16 |
20210388319 | EXPANSION OF HEMATOPOIETIC STEM CELLS - The present disclosure relates to methods and compositions for expansion of human hematopoietic stem cells. The present disclosure also relates to methods of treatment involving the use of the expanded HSCs. | 2021-12-16 |
20210388320 | DIFFERENTIATION-INDUCED CELL POPULATION FROM WHICH UNDIFFERENTIATED CELLS HAVE BEEN REMOVED, USE OF SAME, AND METHOD FOR PRODUCING SAME - Provided is a cell population comprising differentiated cells obtainable by inducing differentiation of pluripotent stem cells, wherein the content ratio of undifferentiated pluripotent stem cells is 0.2% or less. | 2021-12-16 |
20210388321 | METHODS FOR PRODUCING FIBROADIPOGENIC PROGENITOR CELLS - The present disclosure provides methods of producing a preparation of fibroadipogenic progenitors (FAPs) from a cell mixture. In certain embodiments, the present disclosure provides a method of producing a preparation of human FAPs from a skeletal muscle biopsy sample for later use. | 2021-12-16 |
20210388322 | METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS USING RNA NANOPARTICLES FOR CELL TRANSFORMATION - The present invention pertains to a method for producing induced pluripotent stem cells, and more specifically, to a method for producing induced pluripotent stem cells using RNA nanoparticles for cell transformation, wherein: cell transformation can be effectively performed without genetic modification by producing induced pluripotent stem cells using self-assembled RNA nanoparticles including at least one RNA selected from the group consisting of messenger RNA for expressing transcription factors which induce somatic cells and adult stem cells to be dedifferentiated into induced pluripotent stem cells, micro RNA facilitating the dedifferentiation process, and small interfering RNA; the production efficiency of iPSCs can be maximized by adjusting structural properties and activity; and low gene loading efficiency can be overcome by applying an infinite replication process to incorporate high concentrations of RNA in RNA nanoparticles. | 2021-12-16 |
20210388323 | SYSTEM AND METHOD TO DETERMINE CRITICAL PROCESS PARAMETERS FOR A CONTINUOUS VIRAL INACTIVATION REACTOR TO DESIGN AND MANUFACTURE SAME - A viral inactivation device including at least one experimental continuous viral inactivation reactor having at least an inlet, an outlet, and a tubular flow path and a computer system that, based on the experimental continuous viral inactivation reactor can design, select, make, and/or manufacture a scaled actual reactor. The tubular flow path includes a set of alternating turns that form a serpentine or an interwoven pattern between the inlet and the outlet. | 2021-12-16 |
20210388324 | TRANSFORMED MICROORGANISM AND METHOD OF PRODUCING POLYHYDROXYALKANOATE - Provided is a transformed microorganism that has a polyhydroxyalkanoate synthase gene and in which expression of a minD gene is enhanced. Also provided is a transformed microorganism that has a polyhydroxyalkanoate synthase gene and in which expression of a minC gene and a minD gene is enhanced. In this transformed microorganism, expression of a minE gene may be enhanced or reduced. Also provided is a method of producing a PHA, the method including the step of culturing any of the transformed microorganisms in the presence of a carbon source. | 2021-12-16 |
20210388325 | C-RAF Mutants that Confer Resistance to RAF Inhibitors - Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided. | 2021-12-16 |
20210388326 | SPHINGOSINE KINASE 1 AND FUSION PROTEIN COMPRISING THE SAME AND USE THEREOF - The present invention provides a sphingosine kinase 1, a fusion protein comprising the same, and a use thereof. The sphingosine kinase 1 and the fusion protein comprising the same have significant effects in lowering blood sugar and body weight, and are useful for the preparations of protein drugs for controlling metabolic diseases such as obesity and diabetes. It also provides a protein drug, which is a fusion protein containing a sphingosine kinase 1 or an amino acid sequence having the activity thereof. The fusion protein comprises a sphingosine kinase 1 (SPHK1) or an amino acid sequence having the activity thereof, a FC sequence and a linker sequence. The protein drug can significantly decrease blood sugar, blood fat and body weight, and improve fat metabolism. | 2021-12-16 |
20210388327 | SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF - The present disclosure provides non-natural reverse transcriptases for conducting reverse transcription. The non-natural reverse transcriptases herein may have increased thermostability and can conduct reverse transcription more efficiently than natural reverse transcriptases. | 2021-12-16 |
20210388328 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME - The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases. | 2021-12-16 |
20210388329 | SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF - The invention relates to compositions and methods of constructs comprising a SIRP-α polypeptide, including SIRP-α variants. The constructs may be engineered in a variety of ways to respond to environmental factors, such as pH, hypoxia, and/or the presence of tumor-associated enzymes or tumor-associated antigens. The constructs of the invention may be used to treat various diseases, such as cancer, preferably solid tumor or hematological cancer. | 2021-12-16 |
20210388330 | DEPHOSPHORYLATED LYSOSOMAL STORAGE DISEASE PROTEINS AND METHODS OF USE THEREOF - Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or 12D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II). | 2021-12-16 |
20210388331 | NEURODEGENERATIVE DISORDERS - A cyclic polypeptide, derivative or analogue thereof, comprising an amino acid sequence derived from the C-terminus of acetylcholinesterase (AChE), or a truncation thereof. | 2021-12-16 |
20210388332 | GENE EDITING SYSTEM FOR CORRECTING SPLICING DEFECTS - The present disclosure provides genome editing systems, compositions and methods. The genome editing system comprises at least one nuclease that generates blunt-ended DNA breaks in a sequence-specific manner, wherein the genome editing system is configured to form a first and a second blunt-ended double strand break in an intron of a gene, wherein the intron comprises a splice donor site mutation that alters splice site recognition, thereby excising a segment of the intron and simultaneously joining DNA ends flanking the excised segment of the intron to constitute a functional donor splice site. | 2021-12-16 |
20210388333 | RNA-GUIDED NUCLEASES AND DNA BINDING PROTEINS - Compositions and methods related to Cas proteins, nucleic acids encoding the Cas proteins, and modified host cells comprising the Cas proteins and/or encoding nucleic acids are disclosed. Cas proteins are useful in a variety of applications. Cas proteins bind guide RNAs that in turn provide functional specificity to the Cas proteins, nucleic acids encoding the Cas guide RNAs, and modified host cells comprising the Cas guide RNAs and/or encoding nucleic acids. The Cas polypeptides and corresponding guide RNAs can be used in a variety of applications. | 2021-12-16 |
20210388334 | POLYPEPTIDES WITH ENDOGLUCANASE ACTIVITY AND USES THEREOF - Disclosed herein are cellulase variants, or active fragments thereof, and polynucleotides encoding same, wherein the cellulase variants, or active fragments thereof, have endoglucanase activity. Also disclosed herein are compositions comprising said cellulase variants, or active fragments thereof, vectors and/or host cells comprising the polynucleotides encoding said cellulase variants, or active fragments thereof; and methods for making and/or using said cellulase variants, or active fragments thereof and/or compositions containing same; wherein said cellulase variants, or active fragments thereof, have endoglucanase activity. | 2021-12-16 |
20210388335 | SOUTHERN GREEN STINK BUG PHEROMONE SYNTHESIS ENZYMES AND USES THEREOF - Described herein are engineered polynucleotides and vectors capable of encoding one or more engineered southern green stink bug pheromone synthesis enzymes. Also described herein are engineered southern green stink bug pheromone synthesis enzymes. Also described herein are methods of making modified plants capable of expressing one or more southern green stink bug pheromone synthesis enzymes. | 2021-12-16 |
20210388336 | Mutant of Nitrile Hydratase Derived from Caldalkalibacillus thermarum - The disclosure discloses a mutant of nitrile hydratase derived from | 2021-12-16 |
20210388337 | PROTEIN-POLYMER CONJUGATES AND METHODS FOR THEIR PREPARATION - This document relates to materials and methods for using controlled radical polymerization (e.g., atom transfer radical polymerization) to generate protein-polymer conjugates in which two or more polymer molecules are attached to individual initiator molecules on the protein. | 2021-12-16 |
20210388338 | Methods and Compositions for Messenger RNA Purification - The present invention provides, among other things, methods for purifying mRNA, which involves removing impurities from a messenger RNA preparation synthesized by large scale in vitro transcription process (IVT), by precipitating the IVT-synthesized mRNA in a buffer comprising a denaturing salt in combination with a reducing agent, followed by capturing the precipitated mRNA and dissolving the captured mRNA into a solution to obtain purified mRNA. | 2021-12-16 |
20210388339 | METHOD FOR ENGINEERING IMMUNOGLOBULINS - The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins. | 2021-12-16 |
20210388340 | METHODS FOR IMPROVING TRAITS IN PLANTS - The present invention discloses a method for screening for and identifying a desirable plant improving trait, said method comprises steps of: (a) obtaining genetic material from a sampling of a predefined source and (b) constructing an expression library from said genetic material. The aforementioned method further comprises steps of: (c) producing plants transformed with said expression library at a transformation efficiency of at least 0.05%-30%, representing at least 10 | 2021-12-16 |
20210388341 | MULTISPECIFIC ANTIBODY SCREENING METHOD USING RECOMBINASE MEDIATED CASSETTE EXCHANGE - Herein is reported a method for preparing a recombinant host cell library expressing bispecific antibodies using targeted integration into a host cell comprising an exogenous nucleotide sequence integrated at a site within a locus of the genome of the host cell, wherein the exogenous nucleotide sequence comprises a first and a second recombination recognition sequence flanking at least one first selection marker, and a third recombination recognition sequence located between the first and the second recombination recognition sequence, and all the recombination recognition sequences are different whereby the host cell is transfected with a library of first vectors each comprising two recombination recognition sequences matching the first and the third recombination recognition sequence on the integrated exogenous nucleotide sequence and flanking two exogenous nucleotide sequences and at least one second selection marker, and a library of second vectors each comprising two recombination recognition sequences matching the second and the third recombination recognition sequence on the integrated exogenous nucleotide sequence and flanking at least two further exogenous nucleotide sequences; wherein one of the four exogenous nucleotide sequences encode a first light chain, one a second light chain, one a first heavy chain and one a second heavy chain of the bispecific antibody. | 2021-12-16 |
20210388342 | NUCLEIC ACID LIBRARIES, PEPTIDE LIBRARIES AND USES THEREOF - The present invention relates to nucleic acid libraries, peptide libraries and uses thereof. The invention relates to libraries of nucleic acids that encode a plurality of peptides that represent fragments of naturally occurring proteins. In particular, the invention relates to a library of nucleic acids, each nucleic acid comprising a coding region of defined nucleic acid sequence encoding for a peptide having a length of between 25 and 110 amino acids, and having an amino acid sequence being a region of a sequence selected from the amino acid sequence of a naturally occurring protein of one or more organisms; wherein the library comprises nucleic acids that encode for a plurality of at least 10,000 different such peptides, and wherein the amino acid sequence of each of at least 50 of such peptides is a sequence region of the amino acid sequence of a different protein of a plurality of different such naturally occurring proteins. | 2021-12-16 |
20210388343 | NUCLEIC ACID MOLECULES AND METHODS FOR AAV VECTOR SELECTION - The present disclosure relates generally to nucleic acid molecules and methods for identifying AAV vectors with desirable properties, including nucleic acid molecules and methods useful for identifying novel cap genes for vectorization, production of AAV vectors and AAV libraries. | 2021-12-16 |
20210388344 | METHODS FOR DETERMINING RECOMBINATION DIVERSITY AT A GENOMIC LOCUS - The present disclosure relates to methods for determining recombination diversity at a genomic locus of interest. The method includes fragmenting nucleic acids isolated from immune cells, ligating adaptors to the fragmented or amplified nucleic acids, and selectively amplifying nucleic acids containing a recombined junction at the genomic locus of interest. Selective amplification is achieved by using a first primer that hybridizes to an adaptor sequence and a second primer that hybridizes at a constant region downstream of the recombined junction. The selectively amplified nucleic acids may be sequences and analyzed to determine recombination diversity at the genomic locus. | 2021-12-16 |
20210388345 | PROFILING OF RHEUMATOID ARTHRITIS AUTOANTIBODY REPERTOIRE AND PEPTIDE CLASSIFIERS THEREFOR - The present disclosure provides for compositions and methods for identifying peptide classifiers. In one embodiment, a peptide classifier for diagnosing rheumatoid arthritis includes a composition comprising a plurality of molecules. Each molecule comprises a peptide having a sequence selected from SEQ ID NOS: 1-8861, wherein the plurality of molecules defines a classifier for rheumatoid arthritis. | 2021-12-16 |
20210388346 | HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS - The disclosure generally relates to compositions and methods for the production of nucleic acid molecules. In some aspects, the invention allows for the microscale generation of nucleic acid molecules, optionally followed by assembly of these nucleic acid molecules into larger molecules. In some aspects, the invention allows for efficient production of nucleic acid molecules (e.g., large nucleic acid molecules such as genomes). | 2021-12-16 |
20210388347 | REGULATORY NUCLEIC ACID SEQUENCES - The present invention relates to regulatory nucleic acid sequences, in particular liver-specific cis-regulatory elements, cis-regulatory modules, promoters and other such nucleic acid sequences, that are capable of enhancing liver-specific expression of genes. The invention also relates to expression constructs, vectors and cells comprising such liver-specific regulatory nucleic acid sequences, and to methods of their use. The liver-specific regulatory nucleic acid sequences are of particular utility for gene therapy applications, but also find utility in other areas such as bioprocessing and biotechnology. | 2021-12-16 |
20210388348 | MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING - Chemically modified crRNAs and tracrRNAs are provided. crRNAs and tracrRNAs with 5′ and/or 3′ conjugated moieties are provided. crRNAs and tracrRNAs with modifications in the repeat region of the crRNA or the anti-repeat region of the tracrRNA are provided. Methods of using the crRNAs and tracrRNAs for genome editing with a CRISPR nuclease and kits for performing the same are also provided. | 2021-12-16 |
20210388349 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY - The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided. | 2021-12-16 |
20210388350 | EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE - It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg. | 2021-12-16 |
20210388351 | ARTIFICIAL RNA-GUIDED SPLICING FACTORS - Provided herein, in some aspects, are compositions and methods for artificially modulating alternative splicing, for example, inducing exon inclusion and/or exon exclusion events. In some embodiments, a catalytically inactive programmable nuclease, such as dCasRx, is fused to an RNA-binding protein (or fragment or isoform thereof) and, when guided to a target of interest by a specific guide RNA (gRNA), can regulate alternative splicing in eukaryotic cells. | 2021-12-16 |
20210388352 | COMPOSITION FOR PREVENTING OR TREATING KELOIDS OR HYPERTROPHIC SCARS - The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds. | 2021-12-16 |
20210388353 | OLIGOMERS - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 2021-12-16 |
20210388354 | Methods of Manipulating the Fate of Cells - A method of manipulating the fate of a cell, which comprises contacting the cell with at least one of (a) a cell fate-determining untranslated/noncoding RNA species (cuR), (b) a modified cuR, or (c) a compound that modifies or affects cuR, under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained. Another aspect of the invention relates to a method of manipulating the fate of a cell by contacting the cell with a compound that affects a fate-determining mechanism involving homologous nucleic acid interactions of RNA:RNA or RNA:DNA or resolution of such interactions under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained. The invention generates cell fate or cell maintenance in a subject, such as a human, so that an increase of desirable cells or a decrease in undesirable cells can be obtained in the subject. This feature can be applied to a therapeutic method of treating a condition in a subject. | 2021-12-16 |
20210388355 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES - Methods, kits and devices for dosing a subject to reduce a hypersensitivy response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed. | 2021-12-16 |
20210388356 | MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE - One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions. | 2021-12-16 |
20210388357 | OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN - The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency. | 2021-12-16 |
20210388358 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION - The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs. | 2021-12-16 |
20210388359 | OLIGONUCLEOTIDE FORMULATION METHOD - The present invention relates to a method for determining the amount of an oligonucleotide present in a powdered form. The method does not require the experimental determination of the extinction coefficient of the oligonucleotide or the serial dilution and A260 measurement. The method is, for example, applicable to modified oligonucleotides including 2′ sugar-modified oligonucleotides, phosphorothioate oligonucleotides, reporter labelled oligonucleotides, and conjugated oligonucleotides. | 2021-12-16 |
20210388360 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF PROTEIN C (PROC) GENES - The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. | 2021-12-16 |
20210388361 | MODIFIED NUCLEIC ACID HAVING IMPROVED TREATMENT EFFICACY, AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME - An oligonucleotide variant according to an embodiment of the present disclosure has a structure of Formula 1 may exhibit excellent in-vivo stability and anticancer effects: | 2021-12-16 |
20210388362 | TARGETED NON-VIRAL DNA INSERTIONS - Provided herein are methods and compositions for editing the genome of a cell. In some embodiments, a nucleotide sequence of at least 200 nucleotides in length is inserted into a target region in the genome of a cell. | 2021-12-16 |
20210388363 | MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA - An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided. | 2021-12-16 |
20210388364 | METHOD FOR DETECTING A SPECIFIC SPLICE EVENT OF A GENE OF INTEREST - The invention provides a method for detecting a specific splice event of a gene of interest, wherein the specific splice event creates a specific splice product, which comprises an exon of interest, wherein the method comprises: (i) Inserting a split intein—heterologous polynucleotide construct into the exon of interest, wherein the split intein comprises an N-terminal splicing region upstream of the heterologous polynucleotide and a C-terminal splicing region downstream of the heterologous polynucleotide; and (ii) detecting the heterologous polynucleotide and/or the expression product of the heterologous polynucleotide. The present invention also provides the use of the split intein—heterologous polynucleotide construct, the nucleic acid encoding this construct, the vector and the host cell comprising the nucleic acid as well as a kit for detecting a specific splice event of a gene of interest. | 2021-12-16 |
20210388365 | METHOD FOR ENHANCING VANILLIN RESISTANCE OF SACCHAROMYCES CEREVISIAE BY KNOCKING OUT SNG1 GENE - A method of enhancing vanillin resistance of | 2021-12-16 |
20210388366 | PLANT-PRODUCED CHIMAERIC ORBIVIRUS VLPS - This invention relates to a second generation, plant-produced synthetic | 2021-12-16 |
20210388367 | PLANTS COMPRISING A LOW COPY NUMBER OF RI GENES - Described is a plant transformed with one or more genes originating from the Ri plasmid of | 2021-12-16 |
20210388368 | SCAEVOLA PLANTS WITH RADIALLY SYMMETRICAL FLOWERS - The invention provides | 2021-12-16 |
20210388369 | EXPRESSION MODULATING ELEMENTS AND METHODS OF USE - The disclosure relates to gene expression modulation elements from plants and their use in modulating the expression of one or more heterologous nucleic acid fragments in plants. The disclosure further discloses compositions, polynucleotide constructs, transformed host cells, plants and seeds containing the expression modulating elements, and methods using the same. | 2021-12-16 |
20210388370 | GENES, CONSTRUCTS AND MAIZE EVENT DP-202216-6 - The compositions and methods disclosed relate to DNA compositions, plant cells, seeds, plant parts that relate to maize plants with increased grain yield trait. Also provided are assays for detecting the presence of the maize DP-202216-6 event based on the DNA sequence of the recombinant construct inserted into the maize genome and the DNA sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided. | 2021-12-16 |
20210388371 | NUCLEOTIDE SEQUENCES AND POLYPEPTIDES ENCODED THEREBY USEFUL FOR MODIFYING PLANT CHARACTERISTICS IN RESPONSE TO COLD - Methods and materials for modulating cold tolerance levels in plants are disclosed. For example, nucleic acids encoding cold tolerance-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased levels of cold tolerance and plant products produced from plants having increased cold tolerance levels. | 2021-12-16 |
20210388372 | NOVEL GENE RELATED TO PLANT DROUGHT STRESS TOLERANCE AND USES THEREOF - Disclosed herein are a novel gene for improving drought stress tolerance in plants and a use thereof. Specifically, disclosed is a composition for improving the drought stress tolerance of plants. The composition includes drought responsive ring 1 (DRR1) protein or a gene sequence that encodes the protein. Further disclosed are a plant cell and a plant either of which is transformed with the composition. The composition improves the tolerance of a plant to drought stress. The transformed plant cell or plant has excellent tolerance to drought stress and thus can be usefully used as a novel functional crop that can reduce the loss of crop yield caused by dry environmental stress in the cultivation stage of the plant. | 2021-12-16 |
20210388373 | METHODS FOR GENETIC MODIFICATION OF PLANTS - Described are methods and materials for the genetic modification of plants by specific gene targeting and precise editing of nucleic acid sequences in a plant. The methods and materials provided herein enable one to edit the plant genome by design to control the expression of endogenous genes and/or control the transmission and expression of transgenic traits. Provided are also methods of producing plants having a desirable agronomic trait by crossing a transgenic plant expressing a gRNA with a plant expressing a Cas enzyme, and selecting a progeny plant having the desirable agronomic trait or a seed thereof. | 2021-12-16 |
20210388374 | PSEUDOMONAS PROTEGENS AND PRODUCTS THEREOF TO CONTROL BACTERIAL PANICLE BLIGHT OF RICE - The present invention provides biosynthetic products that may be useful for controlling bacterial panicle blight of rice. These products are encoded by four biosynthetic operons found within the genome of a | 2021-12-16 |
20210388375 | GENES ASSOCIATED WITH RESISTANCE TO WHEAT YELLOW RUST - An isolated nucleic acid encoding a nucleotide-binding and leucine-rich repeat (NLR) polypeptide including a zinc-finger BED domain, wherein expression of the NLR polypeptide in a plant confers or enhances resistance of the plant to a fungus. | 2021-12-16 |
20210388376 | PLANTS AND METHODS FOR CONTROLLING FUNGAL PLANT PATHOGENS - Provided herein are plants that reduce growth of a fungal pathogen, increase resistance of the plant to a fungal pathogen, or a combination thereof. The plant includes a polynucleotide that reduces expression of a coding region present in a fungal pathogen, such as | 2021-12-16 |
20210388377 | PHI-4 POLYPEPTIDES AND METHODS FOR THEIR USE - Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest, as probes for the isolation of other homologous (or partially homologous) genes. The insecticidal proteins find use in controlling, inhibiting growth or killing lepidopteran, coleopteran, dipteran, fungal, hemipteran, and nematode pest populations and for producing compositions with insecticidal activity. | 2021-12-16 |
20210388378 | Chromobacterium Subtsugae Genome - Disclosed herein is the nucleotide sequence of the | 2021-12-16 |
20210388379 | MODIFIED CLOSED-ENDED DNA (CEDNA) COMPRISING SYMMETRICAL MODIFIED INVERTED TERMINAL REPEATS - Described herein are ceDNA vectors having linear and continuous structure can be produced in high yields and used for effective transfer and expression of a transgene. According to some embodiments, ceDNA vectors comprise at least one heterologous nucleotide sequence operably positioned between two flanking symmetric inverted terminal repeat sequences that are not wild-type AAV ITR, wherein all or part of the heterologous nucleotide sequence is under the control of at least one regulatory switch. Some ceDNA vectors provided herein further comprise cis-regulatory elements and provide high gene expression efficiencies. Further provided herein are methods and cell lines for reliable and efficient production of the linear, continuous and capsid-free DNA vectors. | 2021-12-16 |
20210388380 | PROCESS TO PRODUCE KLOTHO PROTEIN IN VITRO - A method of producing Klotho protein includes preparing a Klotho plasmid DNA vector, culturing cells, transfecting the cells with the Klotho plasmid DNA vector in a cell culture medium, growing the transfected cells, and harvesting the cell culture supernatant by removing the transfected cells. The Klotho plasmid DNA vector has a mammalian selection marker and a Klotho open reading frame. The cells are primary fibroblast cells and/or mesenchymal stromal cells. A method of manufacturing a cosmetic composition includes combining Klotho protein or the cell culture supernatant with a cosmetically acceptable vehicle. A method of treating a patient to improve the condition and appearance of aging skin includes topically administering the cosmetic composition to the patient. By upregulating the Klotho gene in vitro and incorporating the Klotho protein and growth factors into a composition, transepidermal water loss, skin atrophy, and free radical damage to the skin may be addressed. | 2021-12-16 |
20210388381 | Hepatocyte Based Insulin Gene Therapy for Diabetes - A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled. | 2021-12-16 |
20210388382 | ADENO-ASSOCIATED VIRUS (AAV) DELIVERY OF ANTI-FAM19A5 ANTIBODIES - The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv. | 2021-12-16 |
20210388383 | MODULAR EXPRESSION SYSTEMS FOR GENE EXPRESSION AND METHODS OF USING SAME - Disclosed herein are compositions and methods for the expression of a gene of interest. The disclosed methods may employ codon-optimization and introduction of non-endogenous restriction sites for efficient expression of a gene. The methods may further employ introduction of a gene variant of interest, such that the disclosed methods, compositions, and systems may be used to determine the significance of a variant of interest. Further disclosed are compositions, systems, and methods for the characterization of gene variants, and other mutations that may impact the function of the protein of interest. | 2021-12-16 |
20210388384 | VECTORS - The present invention provides a kit of vectors comprising a first and second viral vector, wherein the first viral vector comprises a transgene of interest (TOI), and presence of the second viral vector in a host cell is required for integration of the first viral vector TOI into the host cell genome. | 2021-12-16 |
20210388385 | SYNP27 (PROB12), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN PROTOPLASMIC ASTROCYTES - The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 800 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule specifically leads to the expression in protoplasmic astrocytes of a gene when operatively linked to a nucleic acid sequence coding for said gene. | 2021-12-16 |
20210388386 | SYNP57 (PROA14), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN PHOTORECEPTORS - The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in photoreceptors when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule | 2021-12-16 |
20210388387 | SYNP151 (PROC29), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS - The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 550 bp having at least 80% identity to said sequence of SEQ ID NO:1, and uses thereof, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene. | 2021-12-16 |
20210388388 | MUTANT VACCINIA VIRUSES AND USE THEREOF - The present invention discloses recombinant vaccinia virus (VV) virions that are resistant to antiviral defenses and have enhanced anti-tumor activities. In one embodiment, the recombinant VV comprise one or more variant VV proteins that have mutations at one or more neutralizing antibody epitopes, thereby conferring viral escape from the neutralizing antibodies. In another embodiment, the recombinant VV is resistant to complement-mediated neutralization due to the expression of a regulator of complement activation (e.g. CD55). In another embodiment, the recombinant VV has enhanced anti-tumor activities due to the expression of bi-specific antibodies co-targeting cancer cells and immune effector cells, or the expression of a polypeptide blocking the PD-1 pathway. The recombinant vaccinia virus virions can be used to treat cancer in a subject. | 2021-12-16 |
20210388389 | COMPOSITIONS AND METHODS FOR RAPID AND MODULAR GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS - Disclosed are compositions and methods for cellular genome engineering that permit simple, efficient, and versatile permutations of combinatorial or simultaneous knockout and knock-in genomic modifications. An exemplary method includes modifying the genome of a cell by introducing to the cell a Cpf1 endonuclease and one or more AAV vectors encoding one or more crRNAs that direct the endonuclease to one or more target genes. The AAV vectors further contain one or more HDR templates that provide a sequence that encodes a reporter gene, a chimeric antigen receptor (CAR), or combinations thereof, and sequences homologous to one or more target sites. Also disclosed are pharmaceutical compositions containing genetically modified cells and methods of use thereof in treating a subject having a disease or disorder, such as cancer. The disclosed compositions and methods are especially applicable to development of enhanced chimeric antigen receptor engineered T cell therapy (CAR-T). | 2021-12-16 |
20210388390 | INTRACELLULAR DELIVERY OF BIOMOLECULES TO ENHANCE ANTIGEN PRESENTING CELL FUNCTION - The present application provides enhanced antigen presenting cells comprising an agent that enhances the viability and/or function of the antigen presenting cell and/or an antigen and/or an adjuvant, methods of manufacturing such modified antigen presenting cells, and methods of using such modified antigen presenting cells, such as for modulating an immune response in an individual. | 2021-12-16 |
20210388391 | NUCLEIC ACID-GUIDED NUCLEASES - Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods. | 2021-12-16 |
20210388392 | CRISPR-LpCas9 GENE EDITING SYSTEM AND APPLICATION THEREOF - The present invention discloses a CRISPR/LpCas9 gene editing system and application thereof, the CRISPR/LpCas9 gene editing system includes a complex of LpCas9 protein and sgRNA, which can accurately locate a target DNA sequence and cleave DNA double strands. The LpCas9 protein has an amino acid sequence shown in SEQ ID NO:1; and the sgRNA has a nucleotide sequence shown in SEQ ID NO:2, or a modified sgRNA sequence based on SEQ ID NO: 2. The present invention can effectively solve the problems of heterologous codon bias and cytotoxicity in the application of SpCas9 in | 2021-12-16 |
20210388393 | PLGA-PEG/PEI NANOPARTICLES AND METHODS OF USE - Provided herein is a composition comprising a nanoparticle comprising poly(lactic acid-co-glycolic acid) (PLGA)-b-polyethylene glycol (PEG) (PLGA-PEG) copolymer formulated with polyethylenimine (PEI), and one or more cargo molecules (e.g., a nucleic acid molecule with or without a small molecule compound) associated with the nanoparticle. The nucleic acid molecule may be a plasmid or minicircle DNA expressing a gene or genes, CRISPR/Cas9 components, or an RNA molecule (e.g., small interfering RNA, miRNA, or lncRNA). Also provided are methods for delivering a cargo molecule to a cell in vitro and in vivo using the aforementioned composition. | 2021-12-16 |
20210388394 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION - The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms. | 2021-12-16 |
20210388395 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION - The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms. | 2021-12-16 |
20210388396 | CRISPR-BASED GENOME MODIFICATION AND REGULATION - The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence. | 2021-12-16 |
20210388397 | SELECTED PHOSPHOTRANSACETYLASE GENES FOR INCREASED ETHANOL PRODUCTION IN ENGINEERED YEAST - Described are compositions and methods relating to phosphotransacetylase (PTA) genes that improve ethanol production in yeast harboring an engineered PKL pathway, and yeast expressing these PTA genes. Such yeast is particularly useful for large-scale ethanol production from starch substrates, where acetate in an undesirable by-product. | 2021-12-16 |
20210388398 | YEAST EXPRESSING CELLULASES FOR SIMULTANEOUS SACCHARIFICATION AND FERMENTATION USING CELLULOSE - The present invention is directed to cellulytic host cells. The host cells of the invention expressing heterologous cellulases and are able to produce ethanol from cellulose. According to the invention, host cells expressing a combination of heterologous cellulases can be used to produce ethanol from cellulose. In addition, multiple host cells expressing different heterologous cellulases can be co-cultured together and used to produce ethanol from cellulose. Furthermore, the invention demonstrates for the first time the ability of | 2021-12-16 |
20210388399 | ACONITIC ACID EXPORTER (AEXA) INCREASES ORGANIC ACID PRODUCTION IN ASPERGILLUS - Recombinant | 2021-12-16 |
20210388400 | METHOD OF PRODUCING TARGET SUBSTANCE FROM STARTING SUBSTANCE VIA NADH-ACCUMULATING REACTION PATHWAY - Provided is a method of producing a target substance from a starting substance via an NADH-accumulating reaction pathway, the method comprising: incubating bacteria under an aerobic condition; and subsequently incubating the bacteria under an anaerobic condition in the presence of the starting substance and nitrate ion to produce the target substance. | 2021-12-16 |
20210388401 | METHODS OF REFINING A GRAIN OIL COMPOSITION, AND RELATED SYSTEMS, COMPOSITIONS AND USES - The present disclosure relates to methods and systems for refining grain oil compositions using an esterase enzyme component, water, bleaching processes, and combinations thereof, and related compositions produced therefrom having one or more reduced color values. The present disclosure also relates to methods of using said compositions, e.g., as mineral oil replacements. | 2021-12-16 |
20210388402 | cAMP RECEPTOR PROTEIN VARIANT AND METHOD OF PRODUCING L-AMINO ACID USING THE SAME - Provided are a cAMP receptor protein variant, a microorganism including the same, and a method of producing an L-amino acid using the same. | 2021-12-16 |
20210388403 | BIOCATALYTIC METHOD FOR PRODUCING 2H-HBO AND -SUBSTITUTED ANALOGUES FROM LGO USING A CYCLOHEXANONE MONOOXYGENASE - An eco-compatible method is used to synthesize 2H-HBO optionally substituted at the β-position of the lactone function from LGO or a saturated form of LGO such as dihydrolevoglucosenone (2H-LGO) or LGO hydrate (OH-LGO) via a biocatalytic reaction using a cyclohexanone monooxygenase (CHMO). | 2021-12-16 |
20210388404 | ENZYMATIC PRODUCTION OF TAGATOSE - Disclosed herein are improved processes for making tagatose including the steps of converting F6P to T6P, catalyzed by a F6PE; and converting the T6P to tagatose, catalyzed by a T6PP, using enzymes with higher activities compared to F6PEs and T6PPs previously used in a process to produce tagatose. | 2021-12-16 |
20210388405 | METHOD FOR PRETREATING LIGNOCELLULOSIC BIOMASS - The present invention describes a process for pretreatment of lignocellulosic biomass that comprises the step of contacting a lignocellulosic biomass with an ionic liquid consisting of a phthalic salt of dicholine in the weight ratio from 1:1 to 1:100 of biomass:ionic liquid, said step taking place for a period of time that varies from 0.4 to 48 hours and in a temperature range that varies from 60 to 200° C. Furthermore, the present invention also relates to the use of the pretreated lignocellulosic biomass in an enzymatic hydrolysis process. | 2021-12-16 |
20210388406 | MALTOTRIOSE-GENERATING AMYLASE - A maltotriose-generating amylase has an amino acid sequence of any one three polypeptides. One or more amino acids can be substituted, added, inserted, or deleted, such that the polypeptides have at least 70% sequence identity with the amino acid sequences of the polypeptides. The polypeptides are encoded by DNA, which can be included in recombinant vectors. Transformants can be obtained by transforming a host with the DNA. | 2021-12-16 |
20210388407 | CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN - The instant application provides a method for screening batches of soy hydrolysate for a desired amount of a component thereof, such as ornithine or putrescine, and selecting only those batches of soy hydrolysate that have a desired amount of such component. The present disclosure also sets forth methods for culturing cells in media supplemented with selected batches of soy to produce more consistent, high quality lots of a protein of interest. Further, the present disclosure provides a plurality of protein preparations that have each been produced by culturing cells in media supplemented with separate batches of soy hydrolysate containing a desired amount of ornithine or putrescine, whereby each batch of protein produced exhibits improved quality of the protein of interest or amount of quality protein produced. | 2021-12-16 |
20210388408 | CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN - The instant application provides a method for screening batches of soy hydrolysate for a desired amount of a component thereof, such as ornithine or putrescine, and selecting only those batches of soy hydrolysate that have a desired amount of such component. The present disclosure also sets forth methods for culturing cells in media supplemented with selected batches of soy to produce more consistent, high quality lots of a protein of interest. Further, the present disclosure provides a plurality of protein preparations that have each been produced by culturing cells in media supplemented with separate batches of soy hydrolysate containing a desired amount of ornithine or putrescine, whereby each batch of protein produced exhibits improved quality of the protein of interest or amount of quality protein produced. | 2021-12-16 |
20210388409 | PPROCESS FOR PRODUCING A RECOMBINANT FRAGMENT OF THE C-TERMINAL REGION OF THE FLAVIVIRUS NONSTRUCTURAL SOLUBLE PROTEIN NS1, PURIFICATION PROCESS, PRODUCT, USE OF THE PRODUCT, METHOD OF DETECTION AND METHOD OF DIAGNOSIS - The present invention is within the Molecular Biology and Biochemistry and Biotechnology fields. More specifically, the present invention describes a process for producing the recombinant fragment of the c-terminal region of the flavivirus NS1 non-structural soluble protein and the recombinant protein (Zv-ΔNS1) in large scale. The product of the invention has advantageous characteristics as a result of the process for obtaining the same, notably regarding folding and the immunological characteristics suitable for the development of serological tests to detect Zika virus. There are also described a purification process, its use and a method of detecting interaction, and a method of diagnosing diseases caused by a flavivirus. | 2021-12-16 |
20210388410 | MUTANT STRAIN OF TRICHODERMA REESEI, AND PROTEIN MANUFACTURING METHOD - A mutant strain of | 2021-12-16 |
20210388411 | RECOMBINANT EXPRESSION VECTOR APPLICABLE TO RAPID SCREENING FOR RECOMBINANT STRAIN AND APPLICATION - The present invention relates to the field of genetic engineering, particularly to a recombinant expression vector for rapidly screening the high expression strains and a method for rapidly screening high expression strains. In the invention, an exogenous red fluorescent protein and | 2021-12-16 |
20210388412 | BLOOD GLUCOSE MEASUREMENT REAGENT, SENSOR CHIP, AND BLOOD GLUCOSE METER SET - A blood glucose measurement reagent includes glucose dehydrogenase; a chromogenic indicator; and an aromatic hydrocarbon having at least one sulfonic acid group. | 2021-12-16 |